Pfizer asks FDA to expand COVID-19 vaccine authorization to include 12- to 15-year-olds

0

Shares of Pfizer Inc.
PFE,
+1.78%
gained 1% in trading on Friday after the drug maker said it requested that the emergency-use authorization for its COVID-19 vaccine be amended to include teens between the ages of 12 and 15. The vaccine is currently authorized for people who are at least 16 years old in the U.S. Pfizer said a Phase 3 clinical trial in 12- to 15-year-olds found that the vaccine is 100% efficacious and had a similar side-effect profile to past study participants between the ages of 16 and 25. Pfizer developed the vaccine with BioNTech SE
BNTX,
+6.68%.
Pfizer’s stock is down 1.3% since the start of the year, while the broader S&P 500
SPX,
+0.77%
is up 8.5%.

Source

- Advertisement -

Leave A Reply

Your email address will not be published.